Scope: This file is one segment of a multi-part CareSource medical-benefit drug prior authorization policy covering numerous medical-benefit drugs with indication-specific PA criteria, exclusions, required information, age and prescriber restrictions, and coverage durations.
Coverage stance: Mixed — some products are covered when detailed criteria are met; many entries include exclusions and denial rules.
Common themes / operational points:
- Prior authorization required for listed drugs; prescribers must submit diagnosis, prior therapy history, and specified labs/genetic/biomarker tests when required.
- Specialist prescriber or consultation frequently required (examples: rheumatologist for Actemra; pulmonologist for Arikayce; oncologist for many oncology agents).
- Concurrent-use exclusions are common (e.g., no concurrent biologic DMARD/targeted synthetic DMARD; no combination with other CGRP inhibitors).
- Authorization durations are commonly 1 year or “through end of plan year”; some initial approvals are shorter (examples: 4 months, 6 months, 8 months).
- Continuation approvals typically require prescriber documentation of patient response/benefit.
Major drug categories included in this part:
- Oncology agents (targeted therapies, antibody–drug conjugates, immunotherapies) — multiple tumor- and biomarker-specific criteria (e.g., BRAF, RET, FGFR2, NTRK, MET, IDH, KRAS).
- Biologics / immunology (rheumatology, dermatology, gastroenterology) — many with step requirements and exclusion of concomitant biologics/JAK inhibitors.